Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma
Published in: Blood
Access to document
10.1182/blood.2025032044
The B-cell maturation antigen (BCMA)-targeting bispecific T-cell engager (BiTE®) pavurutamab (AMG 701) directs the cytotoxic T-cell response toward multiple myeloma (MM) cells. This phase 1/1b, open-label, dose-exploration and dose-expansion study evaluated the safety, tolerability, and efficacy of pavurutamab monotherapy in patients with triple-class relapsed/refractory MM (RRMM). Pavurutamab (5-18,000 µg) was administered intravenously weekly with step-up dosing in week 1. Overall, 172 patients received at least one dose of pavurutamab; 73 received the recommended phase 2 dose (RP2D; 18,000 µg), with two different step-up dosing regimens in phase 1b....
Hans C Lee, Wouter J Plattel, Simon J Harrison, Douglas W Sborov, Suzanne Lentzsch, Andrew Spencer, Ruben Niesvizky, Suzanne Trudel, Peter Mollee, Ravi Vij, Monique C Minnema, Leo Rasche, Vijay V Upreti, Di Zhou, Qing Xia, Mihaela Talpes, Tobias Eggert, Prashant Kapoor, Sikander Ailawadhi
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
Published in: Lancet Oncology
Access to document
10.1016/S1470-2045(26)00131-2
BACKGROUND: Patients with stage III, human epidermal-growth-factor-receptor 2 (HER2; also known as ERBB2)-negative breast cancer with homologous recombination deficiency (HRD) had a 4-year overall survival of 35% after anthracycline-based chemotherapy versus 78% after intensified alkylating chemotherapy with autologous stem cell rescue (IACT) in a post-hoc analysis of an earlier randomised controlled trial. In this study, we aimed to prospectively assess 4-year overall survival with IACT and establish whether this approach remains superior to a contemporary HRD-targeting regimen in patients with HER2-negative breast cancer with HRD. METHODS: This open-label,...
Rianne L Seefat, Sonja B Vliek, Vincent M T de Jong, Sara Balduzzi, Ingrid A Mandjes, Valesca P Retèl, Inge Eekhout, Marjolein Delfos, Margaret Schot, Marjo J Holtkamp, Mandy M van Rosmalen, Brenda Leeneman, Hedwig Blommestein, Alwin D R Huitema, Efraim H Rosenberg, Petra M Nederlof, Terry W S Chan, Anna van Rhenen, Marielle J Wondergem, Nicolaas P M SchaapTjeerd J F Snijders, Marjolein W M Van der Poel, Wouter J Plattel, Erik van Werkhoven, Harm van Tinteren, Marjolein L Smidt, Jelle Wesseling, Jos Jonkers, Sven Rottenberg, Marie-Jeanne T F D Vrancken Peeters, Carlijn Voermans, John H Maduro, Judith R Kroep, Carolien P Schroder, Evelien J M Kuip, Anthony Gonçalves, Janine Nuver, A N Machteld Wymenga, Rhodé M Bijlsma, Elsken van der Wall, Inge R H M Konings, Vivianne C G Tjan-Heijnen, Mojca Jongen-Lavrencic, Agnes Jager, Sabine C Linn
Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
Published in: Journal of Cancer Survivorship
Access to document
10.1007/s11764-024-01694-0
document
Purpose: Studies looking into the concordance between late effects reported by physicians vs. those reported by Hodgkin lymphoma (HL) survivors are missing. Methods: A Life Situation Questionnaire focusing on late effects collected data from 1230 HL survivors (median follow-up 14.3 years). Twenty-six disease- and treatment-related late effects from various organ systems were matched with physician-recorded data. The concordance between physicians and survivors was systematically evaluated using percentage agreement and kappa statistics. Potential non-responder biases and associations with patient and disease characteristics were also investigated. Results: Agreement levels (indicated by...
Sidsel J. Juul, Sára Rossetti, Berthe M.P. Aleman, Flora E. van Leeuwen, Marleen A.E. van der Kaaij, Francesco Giusti, Paul Meijnders, John M.M. Raemaekers, Hanneke C. Kluin-Nelemans, Michele Spina, Daphne Krzisch, Camille Bigenwald, Aspasia Stamatoullas, Marc André, Wouter J. Plattel, Martin Hutchings, Maja V. Maraldo
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Published in: HemaSphere
Access to document
10.1002/hem3.70422
document
Hodgkin lymphoma (HL) is a B-cell-derived malignancy often affecting young adults. Allocation into risk groups is based on staging with positron emission tomography and computed tomography (PET/CT) and the presence or absence of risk factors. Standard treatment for early-stage favorable classic HL (cHL) consists of two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), followed by 20 Gy involved-site radiotherapy (IS-RT). Two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) or a procarbazine-free eBEACOPP variant plus two cycles of ABVD, followed by 30 Gy IS-RT in...
Dennis A Eichenauer, Marc André, Peter Borchmann, Graham P Collins, Ian Doherty, Hans-Theodor Eich, Massimo Federico, Alexander Fossa, Sylvia Hartmann, Martin Hutchings, Timothy Illidge, Carsten Kobe, Wouter J Plattel, Lena Specht, Anna Sureda, Jan M Zaucha, Joseé M Zijlstra, Igor Aurer
Impact of Rituximab Maintenance on Survival in Patients with Mantle Cell Lymphoma; a Population-based Cohort Study
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2025018667
document
Newly diagnosed mantle cell lymphoma (MCL) is commonly treated with rituximab (R) combined with anthracycline-based chemotherapy, with or without autologous stem-cell transplantation (ASCT). While rituximab maintenance (RM) in clinical trials has been shown to prolong overall survival (OS), its impact at population level remains largely unknown. This study evaluates the effect of RM on outcome of patients with MCL. Patients aged ≥18 years diagnosed with MCL between 1989-2020 were identified using the Netherlands Cancer Registry, and categorized into periods reflecting R and RM implementation (1989-2000, 2001-2014, 2015-2020). Treatment...
Floriske G Stedema, Mirian Brink, Francien Huisman, Rozemarijn Van Rijn, Aniko Sijs-Szabo, Inger S Nijhof, Arjan Diepstra, Vibeke K J Vergote, Gwendolyn van Gorkom, Thijs W H Flinsenberg, Gerwin A Huls, Tom van Meerten, Jeanette Doorduijn, Wouter J Plattel, Marcel Nijland